The approved drugs for RRMS are: Two interferons (interferon beta-1a and interferon beta-1b), glatiramer acetate, mitoxantrone, teriflunomide,[REF] dimethyl fumarate,[REF] one S1P modulator (fingolimod) and finally three monoclonal antibodies (natalizumab, alemtuzumab[REF] Daclizumab[REF][REF] and since March 2017 Ocrelizumab[REF]).
Only one of them, Mitoxantrone, has been approved for Secondary Progressive MS (SPMS) and for the special course of PPMS "rapidly progressive multiple sclerosis".,[REF] and also one of them (Ocrelizumab) is approved for Primary Progressive (PPMS).